IGM Biosciences, Inc.
IGMS
$1.22
$0.032.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -36.71% | 1.38% | 179.91% | -4.79% | 75.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.71% | 1.38% | 179.91% | -4.79% | 75.00% |
| Cost of Revenue | -55.64% | -15.74% | -24.63% | -13.91% | 16.54% |
| Gross Profit | 55.88% | 15.90% | 26.29% | 14.00% | -16.05% |
| SG&A Expenses | -84.69% | 50.00% | -17.98% | -18.95% | -1.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.86% | -3.52% | -23.37% | -14.94% | 12.90% |
| Operating Income | 61.11% | 3.55% | 24.71% | 15.02% | -12.49% |
| Income Before Tax | 39.38% | 0.52% | 25.52% | 15.88% | -14.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.62% | 0.90% | 25.64% | 16.01% | -15.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.62% | 0.90% | 25.64% | 16.01% | -15.44% |
| EBIT | 61.11% | 3.55% | 24.71% | 15.02% | -12.49% |
| EBITDA | 63.57% | 3.75% | 25.67% | 16.25% | -12.41% |
| EPS Basic | 40.63% | 2.66% | 44.48% | 37.87% | 14.63% |
| Normalized Basic EPS | 52.68% | 2.27% | 44.39% | 40.29% | 17.85% |
| EPS Diluted | 40.63% | 2.66% | 44.48% | 37.87% | 14.63% |
| Normalized Diluted EPS | 52.68% | 2.27% | 44.39% | 40.29% | 17.85% |
| Average Basic Shares Outstanding | 1.70% | 1.81% | 33.93% | 35.19% | 35.23% |
| Average Diluted Shares Outstanding | 1.70% | 1.81% | 33.93% | 35.19% | 35.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |